Stay updated with breaking news from Patients With Type. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
US patients aged 10 years and older can now benefit from FARXIGA for type-2 diabetes Approval based on results from T2NOW, one of the largest pediatric type-2 diabetes Phase III trials to date ...
From the relationship between glucose fluctuations and cognition in patients with type 1 diabetes to augmentation strategies for treatment-resistant depression, here are highlights from the week in Psychiatric Times.
Discover the potential of SGLT2 inhibitors- a class of diabetes drugs, in mitigating kidney stones risk in diabetic patients.
<p>Type 2 diabetes is associated with increased risk of kidney stones, but some forms of treatment for this condition may also have the benefit of lowering risk of kidney stones. In a study led by investigators from <a href="https://www.massgeneralbrigham.org/" target="_blank">Mass General Brigham</a>, researchers found that there was an association between the use of sodium-glucose contratransporter 2 (SGLT2) inhibitors and a lower risk of developing kidney stones. Their findings are reported in <a href="https://jamanetwork.com/journals/jamaintern...
Compared to glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors, Use of sodium-glucose cotransporter 2 inhibitors was linked to a decreased risk of nephrolithiasis in patients with type 2 diabetes.